In summary, PARP-1 gene rs3219073 polymorphism may predict the efficacy of radiotherapy and provide new therapeutic targets to improve the radiotherapy sensitivity of NSCLC patients. This evidence concerns the gene PARP1 and non-small cell lung carcinoma.